616196-32-8

Upstream product

• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 825-99-0 3-methylsulfanyl-benzoic acid 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 770-04-7 3-(methylsulfanyl)benzoyl chloride 

Downstream Products

• 1187836-97-0 [3-(methylsulfanyl)phenyl](1-methyl-1H-tetrazol-5-yl)methanone 
• 1187836-98-1 N-hydroxy-1-[3-(methylsulfanyl)phenyl]-1-(1-methyl-1H-tetrazol-5-yl)methanimine 
• 1187836-73-2 N-[(2-bromo-1,3-thiazol-4-yl)methoxy]-1-[3-(methylsulfanyl)phenyl]-1-(1-methyl-1H-tetrazol-5-yl)methanimine 
• 1187837-01-9 4-{[({[3-(methylsulfanyl)phenyl](1-methyl-1H-tetrazol-5-yl)methylene}amino)oxy]methyl}-1,3-thiazol-2-amine 
• 1187837-00-8 6-{[({[3-(methylsulfanyl)phenyl](1-methyl-1H-tetrazol-5-yl)methylene}amino)oxy]methyl}pyridin-2-amine 
• 1187836-76-5 N-{[2-(cyclopropylethynyl)-1,3-thiazol-4-yl]methoxy}-1-[3-(methyl-sulfanyl)phenyl]-1-(1-methyl-1H-tetrazol-5-yl)methanimine 
• 1187836-70-9 N-hexyl-6-{[({[3-(methylsulfanyl)phenyl](1-methyl-1H-tetrazol-5-yl)methylene}amino)oxy]methyl}pyridin-2-amine 
• 1187836-78-7 4-{[({[3-(methylsulfanyl)phenyl](1-methyl-1H-tetrazol-5-yl)methylene}amino)oxy]methyl}-N-(3-phenylpropyl)-1,3-thiazol-2-amine 
• 1187836-99-2 2-(6-{[({[3-(methylsulfanyl)phenyl](1-methyl-1H-tetrazol-5-yl)methylene}amino)oxy]methyl}pyridin-2-yl)-1H-isoindole-1,3(2H)-dione 
• 1187836-72-1 N-(2-cyclohexylethyl)-6-{[({[3-(methylsulfanyl)phenyl](1-methyl-1H-tetrazol-5-yl)methylene}amino)oxy]methyl}pyridin-2-amine 
• 1187837-10-0 tert-butyl (2-cyclohexylethyl)(6-{[({[3-(methylsulfanyl)phenyl](1-methyl-1H-tetrazol-5-yl)methylene}amino)oxy]methyl}pyridin-2-yl)carbamate 
• 874899-38-4 ethyl 2-amino-5-[3-(methylthio)benzyl]-1,3-thiazole-4-carboxylate 
• 874899-37-3 ethyl 3-bromo-4-[3-(methylthio)phenyl]-2-oxobutanoate 
• 874899-36-2 ethyl 4-[3-(methylthio)phenyl]-2-oxobutanoate 

Relevant academic research and scientific papers

SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS

The present invention relates to a compound of the general formula (I). The compounds of formula I are useful for treatment of a cardiac disease, disorder or condition in a mammal.

Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema: Part 2

Novel thiazole derivatives were synthesized and evaluated as vascular adhesion protein-1 (VAP-1) inhibitors. Although our previous compound 1 showed potent VAP-1 inhibitory activity, the activity differed between humans and rats. This issue was overcome by a hybrid design using human VAP-1 specific inhibitor 2, which was found by high-throughput screening (HTS), a docking study of a human VAP-1 homology model, and an analysis of sequence information for humans and rats. As a result, we identified compound 35c, which showed strong VAP-1 inhibitory activity (human IC50 of 20 nM; rat IC50 of 72 nM) and significant inhibitory effects in the ex vivo test.

FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES

The present invention relates to hydroximoyl-tetrazole derivatives, their process of preparation, preparation intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of p

THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY

A compound of the formula (I), (II), (III) or (IV): wherein each symbol is as defined in the specification,or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.

2-(2,6-dichlorophenyl)-diarylimidazoles

The invention is directed to compounds of formula (I), which are valuable therapeutics for the treatment of cancer and related diseases.